Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Biotechnology firm Enanta Pharmaceuticals has launched efforts to identify direct-acting antiviral drug candidates to treat Covid-19 coronavirus infection.

The company will leverage its virology expertise, working on paritaprevir and glecaprevir discovery, protease inhibitors for hepatitis C virus (HCV).

Previously, Enanta developed drug candidates for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).

The company is analysing existing compounds within its antiviral compound library for potential anti-SARS-CoV-2 activity.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, the company launched a drug discovery programme by leveraging its expertise in direct-acting antiviral mechanisms to identify candidates for Covid-19.

Enanta Pharmaceuticals president and CEO Jay Luly said: “Based on our proven track record in virology and our capabilities in respiratory diseases, we believe our core competencies position us well to discover a potential treatment for Covid-19.

“Our decision to initiate a programme for Covid-19 is a natural evolution of our work and mission. Not only has Enanta already worked on the discovery of two direct-acting antivirals for HCV, we have an HBV treatment in clinical development, as well as expertise in RSV, a common illness in children that is also responsible for an estimated 177,000 older adult hospitalizations and 14,000 deaths annually in the US.”

Recently, the company launched a Phase IIb clinical trial for the treatment of adults with community-acquired RSV. It will also start a Phase II dose-ranging study in paediatric RSV patients and a Phase II trial in adult transplant patients with RSV.

Similar to Covid-19 profile, elderly people and those with weak immune systems are at higher risk for RSV.